Literature DB >> 25075090

Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens.

Masahide Kuroki1, Naoto Shirasu2.   

Abstract

Novel treatment strategies for cancer that are based on a more detailed understanding over the tumor biology are based on the latest new technology and are expected to improve the current treatment outcome for patients with cancer. However, many of these strategies still have one common and critical problem, being their limited specificity for tumor cells. In this context, antibodies against tumor-associated antigens (TAAs) are used in several ways to increase the tumor specificity of these novel strategies. Firstly, photodynamic or sonodynamic therapy using anti-TAA antibodies conjugated with new sensitizers offers additional therapeutic approaches. Secondly, re-targeting of T-cell immunotherapy using an anti-TAA antibody fusion protein was shown to be useful for the success of cancer immunotherapy, because the down-regulation of HLA class I molecules in tumor tissues constitutes a major tumor escape mechanism associated with tumor-specific cellular immunity. Thirdly, in oncolytic virotherapy, targeting viral vectors carrying cytolytic activity against tumor tissues by modifying the tropisms with anti-TAA antibodies is also very promising from a practical point of view. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Cancer therapy; monoclonal antibody; novel treatment strategy; review; tumor targeting; tumor-associated antigen

Mesh:

Substances:

Year:  2014        PMID: 25075090

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

2.  Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy.

Authors:  Farideh Hosseinzadeh; Saeed Mohammadi; Foroogh Nejatollahi
Journal:  Rep Biochem Mol Biol       Date:  2017-10

Review 3.  Antibodies: At The Nexus of Antigens and Cancer Vaccines.

Authors:  Zenon Steplewski; Magdalena Thurin; Thomas Kieber-Emmons
Journal:  J Infect Dis       Date:  2015-07-15       Impact factor: 5.226

4.  Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.

Authors:  Fei Chen; Chuming Fan; Xuezhong Gu; Haixi Zhang; Qian Liu; Xiaoli Gao; Jie Lu; Baoli He; Xun Lai
Journal:  Med Sci Monit       Date:  2015-07-21

5.  Differences in predictions of ODE models of tumor growth: a cautionary example.

Authors:  Hope Murphy; Hana Jaafari; Hana M Dobrovolny
Journal:  BMC Cancer       Date:  2016-02-26       Impact factor: 4.430

Review 6.  State of the art in anti-cancer mAbs.

Authors:  S M Chiavenna; J P Jaworski; A Vendrell
Journal:  J Biomed Sci       Date:  2017-02-20       Impact factor: 8.410

Review 7.  Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Authors:  Hanni Uusi-Kerttula; Sarah Hulin-Curtis; James Davies; Alan L Parker
Journal:  Viruses       Date:  2015-11-24       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.